Overall, these data point toward the improvement of imaging and serum biomarkers for CVD risk in patients with psoriasis treated with biologics targeting TNF-α, IL-23 and IL-17; moreover, therapies with biologics, by controlling remote skin inflammation, may have the potential to prevent the development of CVDs. The gene discussed is IL17A; the disease is psoriasis.